Sun Pharmaceutical Industries Limited
Sun pharmaceutical industries ltd is an Indian multinational pharmaceutical company. Sun Pharmaceuticals was founded by Dilip Shanghvi in 1983 in Vapi, Gujarat, with five products to treat psychiatry ailments. It is headquartered in Mumbai, Maharashtra. The company manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (API’s) primarily in India and the United States. It is largest pharma company in India. It offers formulations in various therapeutic areas, such as cardiology, psychiatry, neurology, gastroenterology and diabetology.
The vision of the company is reaching people and touching lives globally as a leading provider of valued medicines. The company’s core values include: quality, reliability, trust, consistency & innovation.
The key products of the company are Pharmaceuticals, Generic drugs, Over-the-counter drugs, Vaccines, Diagnostics, contact lenses, animal health. Some of the other products of the company comprises of warfarin, carbamazepine, etodolac, and clorazepate, as well as anti-cancers, steroids, peptides, sex hormones, and controlled substances. It also produces active pharmaceutical ingredients, over the counter medications, generic medications, anti-retro viral medications and specialty medications.
The awards and achievements of the company – it got listed among the forbes world’s best employers 2020, volini, one of the star products was named in nielsen bases top breakthrough innovation winners India 2020 list and the company ranked no. 1 in pharma sector and no. 16 overall in the business world list of India’s most respected companies, 2020.
The company’s CSR efforts are focused on serving and helping needy and underprivileged communities. Their priority areas include: health, education, drinking water and sanitation.
COVID-19 RESPONSE:
Sun pharma made donations of COVID-19 specific medicines, hand sanitizers and PPEs in countries across the globe. In India, they donated INR 250 Million (Indian Rupees Two Hundred and Fifty Million) of Hydroxychloroquine (HCQS), Azithromycin, other related drugs and hand sanitizers. They quickly re-purposed some of their manufacturing facilities to produce high-quality hand sanitizers making them available to healthcare professionals at the time of need.
They also launched FluGuard® (Favipiravir 200 mg) at an economical price of Rs. 35 per tablet, for the treatment of mild to moderate cases of Covid-19 in India in August 2020.
Their shareholding pattern comprises of Promoter and Promoter Group having 54.48% shares, DII’s having 21.97% shares, Public having 12.05% shares and FII’s having 11.50% shares.
